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Halothane was introduced as an anesthetic in the 1950s and was considered a revolutionary agent 
in the ﬁeld of anesthesia. Soon after, halothane-induced hepatitis became a concern, leading to the 
development of less toxic gases that induced a lower incidence of side eﬀects. Two types of haloth-
ane-related hepatotoxicity have been described: type 1, or mild hepatitis, is associated with elevated 
transaminase levels and self-limiting symptoms, and type 2, or severe hepatotoxicity, is associated 
with acute fatal liver failure and is fatal in most cases. Hepatotoxicity is most likely to be immune-
related, based on much evidence. Free radicals that are produced by the metabolism of halothane in 
the liver can modify cellular proteins and introduce neo-antigens to the immune system. Sensitiza-
tion to these neo-antigens induces a more severe response after multiple exposures; most cases of 
type 2 hepatitis occur after repeated contact. New halogenated anesthetics such as enﬂurane, sevoﬂu-
rane, and desﬂurane, are not metabolized in the liver, causing few cases of sensitization. Compared 
with halothane, these anesthetics are expensive. As a result, replacement of halothane with new halo-
genated anesthetics requires a precise cost-beneﬁt analysis, especially in developing countries that 
have low health care budgets.
  Implication for Health policy/practice/research/medical education:
One of forgotten side eﬀects of medications used for anesthesia is studied in the article. The golden time of diagnosis and thinking the best way of 
prevention trigger each physician’s mind involved in the surgical method of treatment. Reading this article is recommended for all practitioners, 
anesthesiologists, and internists. It also describes an important message from the view of health economic. 
  Please cite this paper as:
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Background
Halothane was synthesized by the British chemist Charles 
Suckling over 2 years of research and testing. Its required con-
centration for anesthesia was predicted, and the drug was tested 
by a well-known anesthesiologist, Michael Johnston, who recog-
nized its superior properties compared with other anesthetics 
that were available at that time (1). Development of halothane 
was considered as a great progress in anesthesiology, and it was 
introduced globally in 1956 (2). Subsequently, several reports of 
postsurgical lethal hepatotoxicity in patients who were anes-
thetized with halothane emerged (3-6). Two types of halothane 
hepatotoxicity have been described. Type 1, or mild hepatitis, is 
associated with elevated transaminase levels and self-limiting 
symptoms, and type 2, or severe hepatotoxicity, is associated 
with acute fatal liver failure, resulting in death in most cases. In 
addition, seeking an ideal drug that was associated with pleas-
ant induction and rapid recovery, these reports led to the syn-
thesis of new agents with greater eﬃcacy and safety. Methoxy-
ﬂurane was introduced in the 1960s and was popular for several 
years, but its dose-related nephrotoxicity prompted the develop-
ment of newer agents (7-9). Several members of this family, such 
as enﬂurane (10), isoﬂurane (11), desﬂurane (12) and sevoﬂurane 
(13) were introduced sequentially. Despite the synthesis of new 
agents with a lower incidence of hepatitis-related side eﬀects 
and development of techniques for faster induction and rapid 
recovery (14), their high cost has limited their use, especially in 
developing countries. Yet, the actual incidence of halothane-
induced hepatitis in large-scale studies has not been signiﬁcant 
(15). Hepatitis has also been reported with newer agents, such 
as desﬂurane, sevoﬂurane, and isoﬂurane (16-18). Thus,  substitu-
tion of halothane with newer agents and its ﬁnancial beneﬁts 
must be examined, especially in developing countries (19). We 
performed a literature search in Pubmed, Medline, and Scopus 
using the following keywords and their combinations: halot-
hane, hepatitis, inhalational anesthetics, and halogenated anes-
thetics. Relevant data, focusing on halothane-induced hepatitis 
and comparing halothane with new halogenated anesthetics 
were extracted and reviewed. 4
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Mechanism
The exact mechanism of halothane-induced hepatotoxicity 
is unknown, but there is strong evidence that the immune sys-
tem mediates hepatitis-related mortality (20). Increased levels 
of circulating immune complexes, rash, and arthralgia, which 
implicate involvement of the immune system, are associated 
with halothane-induced hepatitis (21, 22). In the serum of aﬀect-
ed patients, antibodies against hepatocytes exist (23, 24). Based 
on these observations, it has been hypothesized that the im-
mune system mediates the development of hepatotoxicity. On 
the other hand, greater severe liver dysfunction and necrosis is 
reported among patients with repeated exposure to halothane 
(25), which has strengthened this hypothesis. Known human 
risk factors such as female gender, adulthood, and genetics have 
been used to develop an animal model of halothane hepatitis, 
in which severe hepatitis with lesions, similar to halothane hep-
atitis in humans, has been produced (26). Although more severe 
form of hepatic damage is believed to be immune-mediated, 
mild forms of hepatic injury following halothane exposure are 
attributed to the intracellular metabolism of halothane and 
local alterations in hepatic blood ﬂow and oxygen demand, re-
sulting in hepatic hypoxia (27). Halothane undergoes hepatic 
oxidative or reductive metabolism to a greater extent than oth-
er inhalational anesthetics (27, 28), which is primarily mediated 
through cytochrome P450 (CYP450) (29-31). Under normal con-
ditions, up to one-third of halothane is metabolized through 
the oxidative pathway and catalyzed by cytochrome P450 2E1 
and 2A6 while;less than 1% is metabolized through the reductive 
pathway (27, 30, 32).Triﬂuoroacetylchloride (TFA), an extremely 
reactive molecule, is generated by the reaction between lysine 
and halothane metabolites (30-32), which yields neo-antigens by 
binding to the hepatocyte macromolecules (33-36). These neo-
antigens can provoke immune responses against hepatocytes 
and induce fulminant hepatitis (22, 29, 37). Neo-antigens can also 
be expressed on Kupﬀer cells, rendering the antigen-presenting 
cells (38, 39). These results implicate the immune response in 
the development of fulminant halothane-related postsurgical 
hepatic dysfunction. Lethal hepatocyte necrosis rises in serum 
aminotransferase levels, lipid peroxidation, and inactivation of 
CYP450 can be induced by free radicals that are produced dur-
ing nonoxidative halothane metabolization (40-42). This can 
be considered for milder forms of halothane-induced hepatitis, 
because only a small amount of halothane is degraded through 
non-oxidative pathway (43, 44). Although less frequent, hepatic 
failure has been reported following exposure to enﬂurane (45), 
isoﬂurane (46) and desﬂurane (47). Only 2.4% of enﬂurane is de-
graded (48), causing few cases of hepatotoxicity (49, 50). Less 
than 0.2% of desﬂurane is metabolized (51). In contrast, desﬂu-
rane is strongly stable, with just 0.01% metabolism (52). Conse-
quently, based on the model of immune-mediated hepatotoxic-
ity, Desﬂurane should be the ideal inhaled anesthetic, because it 
causes the least free radical formation. 
Manifestation
Two types of halothane-induced hepatotoxicity have been 
described, based on the severity of symptoms: mild hepatitis 
with elevations in aminotransferase levels and self-limiting 
symptoms (53-55), and severe hepatitis (or acute liver failure). 
Halothane degradation products and local hypoxia, due to in-
suﬃcient blood supply and altered oxygen consumption, are   
chief causes of mild form of hepatotoxicity (27). This condition 
usually presents as elevated liver transaminase levels follow-
ing surgery. Some patients develop self-limited rash, arthralgia, 
lethargy, nausea and fever (15, 56-58). common manifestations 
of sever halothane-induced hepatitis are fever, anorexia, nausea, 
myalgia, arthralgia and rash Common manifestations of severe 
halothane-induced hepatitis (59). Hepatomegaly and jaundice 
are also frequently observed, and eosinophilia has been report-
ed in approximately 40% of patients, highlighting the immuno-
logical basis of this condition (60).
Diagnosis
Halothane-induced hepatitis is a diagnosis of exclusion. Ele-
vated serum aminotransferase levels, rash, arthralgia, jaundice 
and hepatomegaly are observed in various hepatic diseases and 
do not necessarily conﬁrm a diagnosis. In contrast, other pos-
sible diagnoses such as surgical complications, preoperative hy-
potension, sepsis, infection, hepatotoxicity due to other drugs 
and viral hepatitis, should be considered.
Treatment
Most cases of halothane-induced hepatitis are managed by 
supportive care (54). Most mild cases do not need intensive care 
and resolve spontaneously with little intervention, but more 
severe fulminant hepatitis requires intensive care. Several treat-
ment modalities such as urgent liver transplantation are eﬃ-
cacious in these patients (54). Resolution of jaundice has been 
reported following methionine therapy in several case reports 
whereas no well-designed studies on this technique have been 
performed (61). Corticosteroids do not have proven eﬃcacy, and 
they might exacerbate the course of hepatitis (61). Patients are 
typically managed according to the complications of acute liver 
failure, such as hepatic encephalopathy, cerebral edema, renal 
failure and metabolic disturbances.
Prevalence
The estimated incidence of halothane-induced hepatitis var-
ies between studies. The largest study was conducted by the 
National Institute of Health, which reviewed approximately 
250,000 cases of halothane exposure; the incidence of severe 
life-threatening hepatic failure was 1/35,000 (25). The incidence 
rate has been reported to range between 1/6000 and 1/35,000 
(62). One of the most signiﬁcant risk factors of severe hepatitis 
is re-exposure to it. After several exposures, these rates can reach 
1/1400 (25). A genetic predisposition has been demonstrated in 
patients with severe hepatitis. Thus, halothane is not recom-
mended in patients who have a family history of halothane sen-
sitization (63-65). In some studies, Caucasian background, obe-
sity, age above 40–50 years and female gender are considered 
risk factors for the severe form of hepatitis (15, 66, 67).
Enﬂurane, Sevoﬂurane, and Desﬂurane 
Since the introduction of halothane, several halogenated an-
esthetics such as enﬂurane, desﬂurane, and sevoﬂurane have 
been developed. Post-exposure liver damage has been attrib-
uted to enﬂurane (50). Based on the protein products of enﬂu-
rane metabolism, it appears that cross-sensitization between 
halothane and enﬂurane is the likely cause of liver damage (45). 
Nonetheless, the principal mechanism of liver damage follow-
ing enﬂurane exposure is unknown (49, 68). Approximately 2% 
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of halothane (27). Because hepatic metabolism, release of free 
radicals and the subsequent neo-antigen production constitute 
the likely mechanism of halogenated anesthetic-induced hepa-
totoxicity, enﬂurane appears to be less hepatotoxic compared 
with halothane. sevoﬂurane, another member of the family, is 
rapidly metabolized, releasing ﬂuoride into the serum (69). Al-
though Sevoﬂurane is associated with liver metabolism (3% to 
5%), it does not aﬀect TFA production, the likely cause of neo-an-
tigen formation (27). Sevoﬂurane is not associated with elevated 
transaminase levels (70), but it decreases liver blood supply 
slightly in animals. Although this ﬁnding has not been demon-
strated in humans, rendered it a safer compound compared with 
halothane (71). Unlike sevoﬂurane, desﬂurane is metabolized in 
the liver to TFA. This may induce protein modiﬁcation (72) and 
immune responses, especially in patients who are sensitized to 
halothane, but the metabolism rate is low (approximately 0.01%) 
(27). Hence, the risk of fatal post-desﬂurane hepatitis is low com-
pared with other halogenated anesthetics. However, few cases 
of hepatitis following desﬂurane might have been sensitized to 
halothane prior to desﬂurane exposure (47). The true expense 
of implementing new anesthetics and substituting halothane 
is not well documented. These costs include the replacement of 
old anesthetic tools with newer methods of vaporizing agents 
and the higher price of new anesthetics. The costs of training 
medical staﬀ should also be included. Further, the number of 
patients who need to be managed with new agents to avoid one 
case of halothane-induced adverse eﬀects must be determined, 
as should the cost of managing that adverse eﬀect (14). Such es-
timates should be assumed in developing countries that have 
low health care budgets and can hardly aﬀord the high costs of 
substituting old technologies with newer and safer ones. Nev-
ertheless, the rare incidence of halothane-induced hepatitis in 
patients without any risk factors complicates the decision. A 
precise cost-beneﬁt analysis must be performed in these coun-
tries before further action. In the absence of large-scale national 
studies, expert panels might be invaluable in determining the 
incidence of side eﬀects.
Discussion
Halothane can cause lethal hepatitis in patients who undergo 
general anesthesia. Thus, the most eﬀective means of protect-
ing patients is to avoid exposure. However, considering the high 
costs of implementing other drugs, especially in developing 
countries, and the rare occurrence of lethal diseases, halothane 
is the logical ﬁrst option. Nonetheless, under special circum-
stances, as illustrated in Table 1 (19), when the probability of 
postexposure hepatitis is considerable, other anesthetics such 
as desﬂurane should be used.
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